Patents Assigned to UCL Business PLC
  • Publication number: 20190309350
    Abstract: A membrane-spanning nanopore is provided that comprises: i. at least one scaffold polynucleotide strand; ii. a plurality of staple polynucleotide strands; and iii. at least one hydrophobically-modified polynucleotide strand, wherein the at least one hydropho-bically-modified polynucleotide strand comprises a polynucleotide strand and a hydrophobic moiety; wherein each of the plurality of staple polynucleotide strands hybridises to the at least one scaffold polynucleotide strand to form the three-dimensional structure of the membrane-spanning nanopore, and wherein the at least one hydrophobically-modified polynucleotide strand hybridises to a portion of the at least one scaffold polynucleotide strand, the membrane-spanning nanopore defining a central channel with a minimum internal width of at least about 5 nm. Membranes comprising the membrane-spanning nanopore and applications of those membranes are also provided.
    Type: Application
    Filed: July 14, 2017
    Publication date: October 10, 2019
    Applicant: UCL BUSINESS PLC
    Inventors: Stefan HOWORKA, Genevieve PUGH, Jonathan Richard BURNS
  • Patent number: 10426845
    Abstract: There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional preproinsulin protein wherein the nucleotide sequence has at least 86% identity to the sequence of SEQ ID NO. 1. Also described are: vectors comprising the nucleic acid molecule for expressing the preproinsulin protein; host cells comprising the nucleic acid molecule or a vector; a transgenic animal comprising cells comprising the nucleic acid molecule or the vector; a pharmaceutical composition comprising the nucleic acid molecule or the vector; a method of treating diabetes comprising administering a therapeutically effective amount of the vector to a patient suffering from diabetes; the nucleic acid molecule for use in therapy; and the nucleic acid molecule or the vector for use in the treatment of diabetes.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 1, 2019
    Assignee: UCL Business PLC
    Inventors: Amit Nathwani, Maria Notaridou
  • Patent number: 10433274
    Abstract: A method and apparatus are provided for calibrating a wireless access point comprising an array of multiple (m) antennas denoted Ai (i=1 . . . m), each antenna having a respective internal phase offset ?i. The method comprises receiving a signal from at least one transmitter located at a substantially known bearing from the wireless access point. The method further comprises determining an estimated value for each internal phase offseti such that an angle of arrival (AoA) spectrum calculated for the received signal on the basis of said estimated values matches the known bearing, wherein said AoA spectrum is calculated by treating said multiple antennas as a phased array. A method and an apparatus are also provided for calibrating a wireless access point comprising first and second arrays of multiple antennas, each antenna array having a respective radio unit, and each antenna in an array having a respective internal phase offseti.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: October 1, 2019
    Assignee: UCL Business PLC
    Inventors: Kyle Jamieson, Jon Gjengset
  • Patent number: 10413598
    Abstract: The invention relates to a new, more potent, coagulation factor IX (FIX) expression cassette for gene therapy of haemophilia B (HB). Disclosed is a vector for expressing factor IX protein, the vector comprising a promoter, a nucleotide sequence encoding for a functional factor IX protein and an intron sequence, wherein the intron sequence is positioned between exon 1 and exon 2 of the nucleotide sequence encoding for a functional factor IX protein, and wherein the intron sequence has at least 80% identity to the sequence of SEQ ID NO. 1 as disclosed herein.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: September 17, 2019
    Assignee: UCL Business PLC
    Inventors: Amit Nathwani, Jenny Mcintosh, Nishil Patel
  • Patent number: 10414803
    Abstract: There is described an AAV capsid protein having an amino acid sequence which has at least 98% identity to the sequence of SEQ ID NO: 3 or at least 94% identity to the sequence of SEQ ID NO: 4. Also described is a pharmaceutical composition, an AAV capsid and a viral particle comprising the capsid protein, a recombinant AAV vector comprising a nucleotide sequence which encodes for the capsid protein, and a host cell and a transgenic animal comprising the capsid protein or the vector. In addition, there is described a method of transferring a nucleic acid of interest into a mammal comprising introducing a recombinant AAV vector into the mammal, wherein the recombinant AAV vector comprises a gene of interest which is encapsidated into a capsid comprising the capsid protein.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: September 17, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Amit Nathwani, Allison Dane
  • Publication number: 20190272450
    Abstract: The invention relates to a control device (1) for a vehicle for determining the perceptual load of a visual and dynamic driving scene. The control device is configured to: receive a sensor output (101) of a sensor (3), the sensor (3) sensing the visual driving scene, extract a set of scene features (102) from the sensor output (101), the set of scene features (102) representing static and/or dynamic information of the visual driving scene, and determine the perceptual load (104) of the set of extracted scene features (102) based on a predetermined load model (103), wherein the load model (103) is predetermined based on reference video scenes each being labelled with a load value The invention further relates to a system and a method.
    Type: Application
    Filed: June 7, 2016
    Publication date: September 5, 2019
    Applicants: TOYOTA MOTOR EUROPE, UCL BUSINESS PLC
    Inventors: Jonas AMBECK-MADSEN, Ichiro SAKATA, Nilli LAVIE, Gabriel J. BROSTOW, Luke PALMER, Alina BIALKOWSKI
  • Patent number: 10391145
    Abstract: The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: August 27, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Dennis Kaetzel, Matthew Charles Walker, Stephanie Schorge, Dimitri Michael Kullmann
  • Publication number: 20190252842
    Abstract: Apparatus and method establish quantum oscillations at room temperature. A cavity has therein a resonator structure that includes a resonant element and a gain medium. A species of the gain medium has an electronic spin multiplicity capable of supporting a two-level spin system. An optical pump pumps the resonator structure and thereby generates microwave output power through stimulated emission of thermal photons. The species of the gain medium is of a sufficiently high concentration such as to have an ensemble spin-photon coupling rate which exceeds both the cavity mode decay rate and the spin-spin decoherence rate. The optical pump pumps the resonator structure using a short pulse of nanosecond duration, or a burst of approximately a millisecond in duration at relatively low instantaneous optical power, to excite said species of the gain medium into a spin-polarized two-level system that exhibits quantum oscillations in the microwave output power.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 15, 2019
    Applicants: Imperial Innovations Limited, UCL BUSINESS PLC
    Inventors: Jonathan David Baxendale BREEZE, Enrico SALVADORI, Chris KAY
  • Patent number: 10376518
    Abstract: The present invention provides a method for inducing CD8+FOXP3+ regulatory T cells in a subject which comprises administering to the subject: (i) a first agent which inhibits p38 phosphorylation; and (ii) a second agent which stimulates T-cell receptor (TCR) signalling. The method may be used to treat and/or prevent an autoimmune and/or inflammatory disease in a subject. The invention also provides compositions and kits for use in such methods.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: August 13, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Shawn Ellis, Clare Notley, Michael Ehrenstein
  • Patent number: 10363015
    Abstract: An ultrasound system comprises an ultrasound unit including: an ultrasound probe including a first set of imaging transducer elements and a second set of localisation transducer elements. The first set of imaging transducer elements are configured to: (i) produce ultrasound imaging transmissions into the human body, wherein the ultrasound imaging transmissions are focussed into an image scan plane, and (ii) receive reflections of the ultrasound imaging transmissions for generating a two-dimensional anatomical image corresponding to the image scan plane. The second set of localisation transducer elements are configured to produce ultrasound localisation transmissions into the human body for locating the medical instrument with respect to the anatomical image, wherein the ultrasound localisation transmissions extend outside the image scan plane.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: July 30, 2019
    Assignee: UCL BUSINESS PLC
    Inventor: Adrien Desjardins
  • Patent number: 10357358
    Abstract: A heart valve prosthesis comprising: a support structure comprising a framework deformable between an expanded state and a compressed state and vice versa; and a flow-control structure, supported by the support structure, for permitting blood flow in a first direction, and for restricting blood flow in a direction opposite to the first direction. At least one end of the support structure comprises a plurality of apexes of the framework. The support structure is collapsible into the compressed state by pulling on the apexes, to enable it to be drawn into a sheath having an inner radial dimension smaller than the radial dimension of the support structure in the expanded state.
    Type: Grant
    Filed: March 30, 2010
    Date of Patent: July 23, 2019
    Assignee: UCL BUSINESS PLC
    Inventors: Gaetano Burriesci, Alexander M. Seifalian, Constantinos Zervides
  • Patent number: 10358485
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 23, 2019
    Assignees: Eisai R&D Management Co., Ltd., UCL Business PLC
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Patent number: 10314924
    Abstract: Methods for treating a human subject who has X-linked Retinitis Pigmentosa (XLRP) or another clinically-defined ophthalmological condition due to a loss-of-function mutation in the gene encoding the retinitis pigmentosa GTPase regulator (RPGR) protein, the method comprising administering to the subject a nucleic acid comprising an adeno-associated viral vector comprising an abbreviated human RPGR cDNA.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: June 11, 2019
    Assignees: Massachusetts Eye & Ear Infirmary, UCL Business PLC, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Michael A. Sandberg, Basil Pawlyk, Alan Finlay Wright, Xinhua Shu, Tiansen Li, Robin Ali
  • Patent number: 10309027
    Abstract: The present invention provides a method for producing a solution of nanosheets, comprising the step of contacting an intercalated layered material with a polar aprotic solvent to produce a solution of nanosheets, wherein the intercalated layered material is prepared from a layered material selected from the group consisting of a transition metal dichalcogenide, a transition metal monochalcogenide, a transition metal trichalcogenide, a transition metal oxide, a metal halide, an oxychalcogenide, an oxypnictide, an oxyhalide of a transition metal, a trioxide, a perovskite, a niobate, a ruthenate, a layered III-VI semiconductor, black phosphorous and a V-VI layered compound. The invention also provides a solution of nanosheets and a plated material formed from nanosheets.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: June 4, 2019
    Assignee: UCL Business PLC
    Inventors: Patrick Linden Cullen, Neal Skipper, David Buckley, Christopher Howard
  • Publication number: 20190154668
    Abstract: The invention provides light-emitting compositions, including lasing and fluorescent compositions. The invention particularly relates to programmable biological substrates, which fluoresce and/or lase, and which have a wide variety of different applications. The invention extends to use of the fluorescent compositions and lasing compositions comprising programmable biological substrates in fabricating lasers, and in various biological imaging applications, such as in assays.
    Type: Application
    Filed: November 20, 2018
    Publication date: May 23, 2019
    Applicant: UCL BUSINESS PLC
    Inventors: John Edward Hales, John Ward, Gabriel Aeppli, Tim Dafforn
  • Patent number: 10286092
    Abstract: The present invention relates to a method of detecting a therapeutic cell expressing a dopamine transporter (DAT) at a central nervous system (CNS) site in a subject, which comprises the administration of a DAT tracer to the subject, wherein the presence of a therapeutic cell which expresses the DAT is determined.
    Type: Grant
    Filed: August 25, 2015
    Date of Patent: May 14, 2019
    Assignee: UCL Business PLC
    Inventors: Martin Pulé, Adam Badar, Louise Kiru, Mark Lythgoe, Adrien Peters
  • Patent number: 10288725
    Abstract: A method and an apparatus are provided for performing passing sensing using wireless digital communications. The wireless digital communications are frame-based with a predefined frame structure. The method includes receiving a reference signal into to a reference channel, wherein the reference signal comprises a direct version of a radio frequency transmission as part of said wireless digital communications; receiving a surveillance signal into a surveillance channel; detecting and extracting portions of the reference signal corresponding to data transmissions based on said predefined frame structure; extracting portions of the surveillance signal corresponding to the extracted portions of the reference signal; performing a cross-correlation on the extracted portions of the reference signal and the surveillance signal to determine a range-Doppler surface; and providing a real-time display of said range-Doppler surface and/or of information derived therefrom.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: May 14, 2019
    Assignee: UCL Business PLC
    Inventors: Bo Tan, Karl Woodbridge, Kevin Chetty
  • Publication number: 20190134155
    Abstract: The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called “DREADD” receptor being characterised by (i) a decreased responsiveness to its endogenous activating ligand (ii) a retained or enhanced responsiveness to an exogenous agonist. The modified receptor is expressed in neurons of a seizure focus in brain of the patient, and an exogenous agonist is administered which activates the modified receptor to reversibly alters the excitability of the neurons in the seizure focus leading to synaptic silencing or other inhibition.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 9, 2019
    Applicant: UCL BUSINESS PLC
    Inventors: Dennis Kaetzel, Matthew Charles Walker, Stephanie Schorge, Dimitri Michael Kullman
  • Publication number: 20190106751
    Abstract: The invention provides methods for detecting single nucleotide variants in lung cancer, especially stage 3a lung adenocarcinoma and lung squamous cell carcinoma. Additional methods and compositions, such as reaction mixtures and solid supports comprising clonal populations of nucleic acids, are provided.
    Type: Application
    Filed: April 17, 2017
    Publication date: April 11, 2019
    Applicants: Natera, Inc., UCL BUSINESS PLC
    Inventors: Bernhard ZIMMERMANN, Tudor Pompiliu CONSTANTIN, Raheleh SALARI, Huseyin Eser KIRKIZLAR, Robert Charles SWANTON, Mariam JAMAL-HANJANI, Christopher ABBOSH, Gareth WILSON
  • Patent number: 10234467
    Abstract: Apparatus for testing the solubility of a medical dosage form includes a chamber (12) for holding a solvent medium (18), in the preferred embodiment a bicarbonate based buffer system. The apparatus also includes a pH probe (66) which is connectable to a supply of carbon dioxide (32, 34), as well as to a supply of helium (40), the supplies being controlled by a control unit (50). The control unit (50) monitors changes in pH of the solvent medium (18) and, as appropriate, feeds pH increasing and/or pH reducing gas from the supplies (32, 34, 40) into the chamber (12). The control unit (50) is able to maintain a uniform pH during testing or to provide a dynamically adjustable pH during testing, for example to three or more different pH levels in order to test the performance of a drug carrier at different levels of acidity or alkalinity for example, mimicking the conditions of the gastrointestinal tract.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: March 19, 2019
    Assignee: UCL Business PLC
    Inventors: Hamid Ali Merchant, John Andrew Frost, Abdul Waseh Basit